Clinical Trial Update: Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating changes in atherosclerotic plaque characteristics using DCE-MRI with alirocumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Hyperlipidemia

Drugs mentioned

• alirocumab (alirocumab)

Snippet

Sponsor: Westside Medical Associates of Los Angeles | Conditions: Atherosclerosis, Hyperlipidemia | Phase 4 | Status: UNKNOWN